Specialty	Psychiatry
Clinical Interests	Psychopharmacology
	Obsessive Compulsive Disorder
	Tourette's Syndrome
	Anxiety Disorders
	Deep Brain Stimulation
Gender	Male
E-mail	wayne.goodman@mssm.edu
Education and Training	MD, Boston University
	Internship, Transitional, Hospital of St. Raphael
	Residency, Psychiatry, Yale-New Haven Psychiatric Hospital

On July 1, 2009, Dr. Goodman was appointed Professor and Chairman of the Department of Psychiatry at the Mount Sinai School of Medicine in New York City.  He is the Esther and Joseph Klingenstein Professor of Psychiatry and Professor in the Department of Neuroscience.

Prior to joining Mt. Sinai, he served as Director, Division of Adult Translational Research and Treatment Development (DATR), at the National Institute of Mental Health in Bethesda, Maryland from 2007-2009. He has conducted pioneering research in the field of Obsessive-Compulsive Disorder (OCD) and is the principal developer of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the gold standard for assessing OCD. He is co-founder of the Obsessive Compulsive Foundation, the national patient advocacy organization for this disorder.

Dr. Goodman is a native of New York City and attended the Bronx High School of Science. A graduate of Columbia University with a BS in electrical engineering, Dr. Goodman received his medical degree from Boston University and completed his internship, residency, and a research fellowship at Yale University School of Medicine where he remained on faculty until 1993 as an Associate Professor.  In 1994, he joined the University of Florida in Gainesville where he served as Chairman of the Department of Psychiatry for nine years. Dr. Goodman has published more than 200 articles in scientific journals and has been principal investigator on NIMH-funded grants since 1992. He is a member of the American College of Neuropsychopharmacology, a Distinguished Fellow of the American Psychiatric Association and member of Florida's Suicide Prevention Council by gubernatorial appointment. He is the 2010 recipient of the Mysell Lecture Award from Harvard University.

As Chair of Psychiatry, Dr. Goodman works closely with the new Mount Sinai Brain Institute to conduct research on neuropsychiatric disorders such as schizophrenia, Alzheimer's disease, and bipolar disorder. Dr. Goodman is an expert psycho-pharmacologist and currently serves as Acting Chair of the Food and Drug Administration's (FDA's) Psychopharmacologic Drug Advisory Committee.

Education and Training	MD, Boston University
	Internship, Transitional, Hospital of St. Raphael
	Residency, Psychiatry, Yale-New Haven Psychiatric Hospital
Board Certification	Psychiatry

Specialty	Psychiatry
Clinical Interests	Psychopharmacology
	Obsessive Compulsive Disorder
	Tourette's Syndrome
	Anxiety Disorders
	Deep Brain Stimulation
Board Certification	Psychiatry

My primary areas of research interest are obsessive compulsive disorder (OCD) and related disorders such as Tourette's Syndrome (TS) in children and adults.  I am interested in advancing the treatment of OCD through a better understanding of its pathophysiology.  During a span of 20 years, I have investigated the phenomenology, neurobiology and treatment of OCD.   In recent years, I have focused on developing approaches to treatment-resistant OCD including the study of Deep Brain Stimulation (DBS).    

Goodman WK, Insel TR. Deep brain stimulation in psychiatry: concentrating on the road ahead. Biol Psychiatry 2009 Feb 15; 65(4): 263-266.

Goodman WK, Murphy TK, Storch EA. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology 2007; 191: 87-96.

Okun MS, Mann G, Foote KD, Shapira NA, Bowers D, Springer U, Knight W, Martin P, Goodman WK. Internal Capsule and Nucleus Accumbens Region DBS: Responses Observed During Active and Sham Programming. J Neurol Neurosurg Psychiatry 2007; 78(3): 310-314.

Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind placebo controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55(5): 553-555.

Murphy TK, Sajid M, Soto O, Shapira N, Edge PJ, Yang M, Lewis M, Goodman WK. Detecting pediatric autoimmune neuropsychiatric disorders associated with strepto-coccus (PANDAS) in children with OCD and tics. Biol Psychiatry 2004; 55: 61-68.

Shapira NA, Liu Y, He AG, Bradley MM, Lessig MC, James GA, Stein DJ, Lang PJ, Goodman WK. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry 2003; 54: 751-756.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psych 1994; 51: 302-308.

Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive- compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psych 1990; 47: 577-585.

Goodman WK, Price LM, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use, and reliability. Arch Gen Psych 1989; 46: 1006-1011.

Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double-blind comparison with placebo. Arch Gen Psych 1989; 46: 36-44.